About half of Americans approve of using weight-loss drugs to treat obesity, AP-NORC poll finds
A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...
How GLP-1 medications are transforming diabetes and weight loss treatment
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
New Atlas4d
Weight-loss breakthrough as new appetite-curbing hormone is found
A brand new candidate for weight-loss treatment is on the table, with scientists uncovering for the first time how a hormone ...
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
MarketWatch16d
White House says popular weight-loss drug Ozempic subject to Medicare talks
The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have ...
Wall Street Journal16d
Wegovy at Higher Dose Achieves Greater Weight Loss in Trial
Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side effects ...
FiercePharma17d
Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy
In the phase 3b STEP UP study, an experimental 7.2-mg semaglutide dose helped patients lose more weight on average at 72 weeks compared to placebo or semaglutide 2.4 mg, which is currently the ...
STAT17d
High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.
Reuters17d
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Jan 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the ...
i20d
How NHS weight-loss jab delays triggered new private clinic boom
More than 90 per cent of weight loss jab users are forced to pay for treatment privately due to their slow roll-out on the NHS Wegovy is only available on the NHS in England via specialist weight ...
Medical News Today20d
As little as 30 minutes of aerobic exercise per week may aid weight loss, reduce fat
Share on Pinterest New research indicates that 30 minutes of exercise a day can help improve weight loss and reduce body fat. Volia Bigel/Stocksy Experts recommend from 150 to 300 minutes of ...